Apixaban—BMY reversed course and said on the 4Q10 CC that the AVERROES and ARISTOTLE studies will be consolidated in the submissions to the FDA and EMA, as we originally expected.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”